Anker Lundemose joined the Company as president and CEO on
1st March 2013. Dr. Lundemose, MD, PhD, DMSc in Medical Microbiology, has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology and anti-infectives. He has a comprehensive international experience and network, and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech startups, large biotech and big pharma, as well as an initial career in academia. He has been CEO of Prosidion Ltd in the UK from 2003 to 2005, Executive Vice President OSI Pharmaceuticals, NYC, US and President of Prosidion Ltd from 2005 to 2009. Dr. Lundemose was Executive Vice President Corporate & Business Development, OSI Pharmaceuticals Inc., from 2009 until Astellas Pharma’s acquisition of OSI in 2010. He has previously held positions as Managing Director at OSI Pharma’s venture arm in Zug, Switzerland, and as Business Development Director at Novo Nordisk, Denmark.

Synne H Røine joined Bionor Pharma as CFO in May 2013.
Ms Røine holds a Master’s degree in business administration from Université des Sciences Sociales, Toulouse, France. Synne H Røine has held the position as Chief Financial Officer of Pronova BioPharma ASA since July 2009. She has worked in Pronova since 2005 where she has played a key role in the financial team from the IPO in 2007 to the acquisition of the Company by BASF in January 2013. Ms. Røine has held various positions in Pronova BioPharma, through which she has gained broad operational, financial and strategic experience.

Vidar Wendel-Hansen, MD PhD, joined the company as CMO on 1 January 2011 from Gilead Sciences, where he was Medical Director for the Nordic and Baltic regions.  He has over 15 years of biotech and pharma industry experience, primarily within pre-clinical and clinical research and development.

Doctorate (1988) from the University of London, UK, on retrovirus receptors (receptor interference and receptor gene mapping). Post-doctoral research at the University of Alabama at Birmingham, USA, (4 years) analysed retrovirus assembly using a variety of molecular biological techniques. Joined the Department of Microbiology and Immunology, The Gade Institute, University of Bergen in 1992 where research continued on HIV and other Lentiviruses in addition to teaching/supervision of students. Promoted to full Professor in 1997. From 2005-2008, member of the Board of Directors for The National Programme for Research in Functional Genomics (FUGE) at the Research Council of Norway.

Gunnar Flåten holds a Master of Science in Business Administration from Norwegian School of Economics (NHH). Experience in finance, sales and administration in Bionor Immuno AS and Bionor AS since 1986. Previous experience as a consultant in an administration and financial institution.

Hilde has background as construction engineer, and within economy and marketing. Various working experience within product development and project administration. Project manager with responsibility for market entry and further international development of soy based nutraceutical products for heart health and weight management in Nutri Pharma ASA. Advisor for several startup companies, mainly within market surveys and search for industrial and financial partners. Started up and been board member of Women`s Health organization in Norway.

Mats Ökvist, PhD, joined the company in November 2011 as Director of Drug and Platform Technologies. He has a background in Structural Biology, with over 10 years of experience from determination and analysis of proteins structures.